Under construction – not a live service
Sign in
Taking people in GermanyPhase 3

Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia

Key facts

Where
Berlin, Leipzig, and Munich, GermanySee the 3 sites
Phase
Phase 3

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 2 and 17 years old?

Source: NCT06953869, who can take part

Where in Germany

  • Advanced Sleep Research GmbHBerlin, GermanyTaking people
  • Velocity Clinical Research Germany GmbHLeipzig, GermanyTaking people
  • ProSomno GmbHMunich, GermanyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Vanda Pharmaceuticals
Trial code
NCT06953869EU 2024-516411-24-00
Record updated
5 June 2026
Original description
This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female pediatric participants with insomnia disorder.Read full original descriptionShow less

A Multicenter, Double-Blind, Randomized Study to Evaluate the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia

This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female pediatric participants with insomnia disorder.

Inclusion: Ability and acceptance to provide written informed consent of the participant or legal guardian (and assent as required); Confirmed clinical diagnosis of insomnia disorder; Males and Females between 2 and 17 years, inclusive; The sleep disturbance must not be a result of another medication.

Exclusion: Inability to dose daily with tasimelteon or previous intolerance to tasimelteon; A positive test for drugs of abuse; Indication of impaired liver function; Pregnant or lactating females.

ClinicalTrials.gov NCT06953869 · EU CTIS 2024-516411-24-00